2024:

Anja Gouliaev, Janna Berg, Rana Bibi, Arman Arshad, Hakon Olav Leira, Kirill Neumann, Christina Aamelfot, Niels L. Christensen and Torben R. Rasmussen: Multi-disciplinary team meetings for lung cancer in Norway and Denmark: results from national surveys and observations with MDT-MODe, Acta Oncologica

Brativnyk A, Ankill J, Helland Å, Fleischer T: Multi-omics analysis reveals epigenetically regulated processes and patient classification in lung adenocarcinoma, Int J Cancer

Chen L, Wang X, Xie N, Zhang Z, Xu X, Xue M, Yang Y, Liu L, Su L, Bjaanæs M, Karlsson A, Planck M, Staaf J, Helland Å, Esteller M, Christiani DC, Chen F, Zhang R: A two-phase epigenome-wide four-way gene-smoking interaction study of overall survival for early-stage non-small cell lung cancer. Mol Oncol

Dyrbekk APH, Warsame AA, Suhrke P, Ludahl MO, Zecic N, Moe JO, Lund-Iversen M, Brustugun OT: Evaluation of NTRK expression and fusions in a large cohort of early-stage lung cancer, Clin Exp Med

Farooqi SJ, Zhao Z, Öjlert ÅK, Thunold S, Juul HV, Bjaanæs MM, Horndalsveen H, Nymoen HMG, Helland Å, Haakensen VD: Serum cytokines as a biomarker for immune checkpoint inhibitor toxicity in patients with pleural mesothelioma, Front Immunol

Førde D, Kilvær T, Pedersen MI, Blix ES, Urbarova I, Paulsen EE, Rakaee M, Busund LR, Donnem T, Andersen S: High density of TCF1+ stem-like tumor-infiltrating lymphocytes is associated with favorable disease-specific survival in NSCLC, Front Immunol

Graabak G, Grønberg BH, Killingberg KT, Halvorsen TO.

Effect of FDG PET-CT for Staging and Radiotherapy Planning – A Comparison of Cohorts From Two Randomized Trials of Thoracic Radiotherapy in Limited-Stage SCLC. JTO Clinical and Research Reports

Grønberg BH, Killingberg KT, Fløtten Ø, Brustugun OT, Hornslien K, Madebo T, Langer SW, Schytte T, Nyman J, Risum S, Tsakonas G: High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial, The Lancet Oncology

Grønberg BH, Killingberg KT, Fløtten Ø, Bjaanaes MM, Madebo T, Langer S, Schytte T, Brustugun OT, Nyman J, Stokke K, Halvorsen TO: Randomized phase II trial comparing the efficacy of standard-dose with high-dose twice-daily thoracic radiotherapy (TRT) in limited disease small-cell lung cancer (LD SCLC)

Gullhaug A, Haakensen VD, De Ruysscher D, Simone CB 2nd, Hotca-Cho AE, Chhabra AM, Hellebust TP, Paulsen EE, Dimopoulos MP, Johansen S: Lung cancer reirradiation: Exploring modifications to utilization, treatment modalities and factors associated with outcomes.

Hektoen HH, Tsuruda KM, Fjellbirkeland L, Nilssen Y, Brustugun OT, Andreassen BK: Real-world evidence for pembrolizumab in non-small cell lung cancer: a nationwide cohort study, Br J Cancer

Hektoen HH, Tsuruda KM, Fjellbirkeland L, Nilssen Y, Brustugun OT, Andreassen BK: Real-world evidence for pembrolizumab in non-small cell lung cancer: a nationwide cohort study, Br J Cancer

Helland Å, Steinskog ESS, Blix ES, Flobak Å, Brabrand S, Puco K, Niehusmann P, Meltzer S, Oppedal IA, Haug Å, Torkildsen CF, Randen U, Gilje B, Lønning PE, Gjertsen BT, Hovland R, Russnes HG, Fagereng GL, Smeland S, Tasken K: Raising the quality of cancer treatment, Tidsskr Nor Laegeforen

Haakensen VD, Öjlert ÅK, Thunold S, Farooqi S, Nowak AK, Chin WL, Grundberg O, Szejniuk WM, Cedres S, Sørensen JB, Dalen TS, Lund-Iversen M, Bjaanæs M, Helland Å: UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma – A phase II randomised trial, Eur J Cancer

Jordhøy MS, Røyset IM, Saltvedt IT, Grønberg BH, Halsteinli V, Døhl Ø, et al.: Geriatric assessment with management for older patients with cancer receiving radiotherapy: a cluster-randomised controlled pilot study. BMC Medicine

Killingberg, Kristin Toftaker, et al.: Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small-cell lung cancer, Lung Cancer

Killingberg KT, Halvorsen TO, Fløtten Ø, Brustugun OT, Langer SW, Nyman J, Hornslien K, Madebo T, Schytte T, Risum S, Tsakonas G: Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small-cell lung cancer, Lung Cancer

Kirill Neumann, Janna Berg, Haseem Ashraf, Johan Isaksson, Aija Knuuttila, Morten H. Borg and Torben R Rasmussen: Adherence to guidelines for incidental pulmonary nodules: insights from a Nordic Survey, Acta Oncologica

Levin N, Killingberg KT, Halvorsen TO, Danielsen S, Grønberg BH: Evaluation of Radiation Therapy Treatment Plans in a Randomized Phase 2 Trial Comparing 2 Schedules of Twice-Daily Thoracic Radiation Therapy in Limited Stage Small Cell Lung Cancer, Int J Radiat Oncol Biol Phys.

Lærum D, Strand TE, Brustugun OT, Gallefoss F, Falk R, Durheim MT, Fjellbirkeland L: Evaluation of sex inequity in lung-cancer-specific survival, Acta Oncol

Lærum D, Strand TE, Brustugun OT, Gallefoss F, Falk R, Durheim MT, Fjellbirkeland L: Evaluation of sex inequity in lung-cancer-specific survival, Acta Oncol

Miceli R, Eriksson H, Lo Russo G, Alfieri S, Moksnes Bjaanæs M, Pietrantonio F, De Cecco L, Prelaj A, Proto C, Franzén J, McDonnell D, Berenguer Pina JJ, Beninato T, Mazzeo L, Giannatempo P, Verzoni E, Crown J, Helland Å, Eustace A: Gender Difference in sidE eFfects of ImmuNotherapy: a possible clue to optimize cancEr tReatment (G-DEFINER): study protocol of an observational prospective multicenter study, Acta Oncol

Nilssen Y, Brustugun OT, Fjellbirkeland L, Grønberg BH, Haram PM, Helbekkmo N, et al.: Small Cell Lung Cancer in Norway: Patterns of Care by Health Region and Survival Trends, Clinical Lung Cancer.

Nilssen Y, Brustugun OT, Fjellbirkeland L, Grønberg BH, Haram PM, Helbekkmo N, Helland Å, Wahl SGF, Aanerud M, Solberg S: Small Cell Lung Cancer in Norway: Patterns of Care by Health Region and Survival Trends, Clin Lung Cancer

Nilssen Y, Brustugun OT, Fjellbirkeland L, Helland Å, Møller B, Wahl SGF, Solberg S: Distribution and characteristics of malignant tumours by lung lobe, BMC Pulm Med

Nilssen Y, Brustugun OT, Fjellbirkeland L, Helland Å, Møller B, Wahl SGF, Solberg S: Distribution and characteristics of malignant tumours by lung lobe, BMC Pulm Med

Nilssen Y, Brustugun OT, Fjellbirkeland L, Grønberg BH, Haram PM, Helbekkmo N, Helland Å, Wahl SGF, Aanerud M, Solberg S: Small Cell Lung Cancer in Norway: Patterns of Care by Health Region and Survival Trends, Clin Lung Cancer

Nilssen Y, Brustugun OT, Fjellbirkeland L, Grønberg BH, Haram PM, Helbekkmo N, Helland Å, Wahl SGF, Aanerud M, Solberg S: Small Cell Lung Cancer in Norway: Patterns of Care by Health Region and Survival Trends, Clin Lung Cancer

Nymoen HMG, Alver TN, Horndalsveen H, Eide HA, Bjaanæs MM, Brustugun OT, et al.: Thoracic radiation in combination with erlotinib—results from a phase 2 randomized trial.

Frontiers in Oncology.

Nymoen HM, Alver TN, Horndalsveen H, Eide HA, Bjaanæs MM, Brustugun OT, Grønberg BH, Haakensen VD, Helland Å: Thoracic radiation in combination with erlotinib-results from a phase 2 randomized trial, Front Oncol

Orstad, Silje, et al.: The challenge is the complexity”–A qualitative study about decision-making in advanced lung cancer treatment, Lung Cancer 183

Puco K, Fagereng GL, Brabrand S, Niehusmann P, Støre Blix E, Samdal Steinskog ES, Haug Å, Fredvik Torkildsen C, Oppedal IA, Meltzer S et al.: IMPRESS-Norway: improving public cancer care by implementing precision medicine in Norway; inclusion rates and preliminary results, Acta Oncol

Rakaee M, Tafavvoghi M, Ricciuti B, Alessi JV, Cortellini A, Citarella F, Nibid L, Perrone G, Adib E, Fulgenzi CAM, Murilo Hidalgo Filho C, Di Federico A, Jabar F, Hashemi S, Houda I, Richardsen E, Rasmussen Busund LT, Donnem T, Bahce I, Pinato DJ, Helland Å, Sholl LM, Awad MM, Kwiatkowski: Deep Learning Model for Predicting Immunotherapy Response in Advanced Non-Small Cell Lung Cancer, DJ.JAMA Oncol

Rakaee M, Tafavvoghi M, Ricciuti B, Alessi JV, Cortellini A, Citarella F, Nibid L, Perrone G, Adib E, Fulgenzi CAM, Murilo Hidalgo Filho C, Di Federico A, Jabar F, Hashemi S, Houda I, Richardsen E, Rasmussen Busund LT, Donnem T, Bahce I, Pinato DJ, Helland Å, Sholl LM, Awad MM, Kwiatkowski DJ: Deep Learning Model for Predicting Immunotherapy Response in Advanced Non-Small Cell Lung Cancer, JAMA Oncol

Rayford A, Gärtner F, Ramnefjell MP, Lorens JB, Micklem DR, Aanerud M, Engelsen AST: AXL expression reflects tumor-immune cell dynamics impacting outcome in non-small cell lung cancer patients treated with immune checkpoint inhibitor monotherapy, Front Immunol

Schaufel MA, Gärtner F, Leivdal BK, Haug SA, Brekke J, Storstein AM, Tveiten ØV, Bødtker JE, Fløtten Ø: A woman in her thirties with confusion Tidsskr Nor Laegeforen

Taranova E, Aanerud M, Halvorsen TO, Killingberg KT, Jordhøy MS, Grønberg BH: Associations Between Patient-Reported Nutritional Status, Toxicity, and Survival in Limited-Stage SCLC. JTO Clinical and Research Reports

Taranova E, Aanerud M, Halvorsen TO, Killingberg KT, Slaaen M, Grønberg BH: Associations Between Patient-Reported Nutritional Status, Toxicity, and Survival in Limited-Stage SCLC JTO, Clin Res Rep

Thunold S, Hernes E, Farooqi S, Öjlert ÅK, Francis RJ, Nowak AK, Szejniuk WM, Nielsen SS, Cedres S, Perdigo MS, Sørensen JB, Meltzer C, Mikalsen LTG, Helland Å, Malinen E, Haakensen VD: Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccine, Eur J Nucl Med Mol Imaging

Werr L, Bartenhagen C, Rosswog C, Cartolano M, Voegele C, Sexton-Oates A, Di Genova A, Ernst A, Kahlert Y, Hemstedt N, Höppner S, Mansuet Lupo et al.: TERT Expression and Clinical Outcome in Pulmonary Carcinoids, J Clin Oncol